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Abstract
Introduction: The nuclear enzyme topoisomerase IIa (TopoIIa) is able to cleave DNA in a reversible manner,
making it a valuable target for agents such as etoposide that trap the enzyme in a covalent bond with the 5′ DNA
end to which it cleaves. This prevents DNA religation and triggers cell death in cancer cells. However, development
of resistance to these agents limits their therapeutic use. In this study, we examined the therapeutic targeting of
geminin for improving the therapeutic potential of TopoIIa agents.
Methods: Human mammary epithelial (HME) cells and several breast cancer cell lines were used in this study.
Geminin, TopoIIa and cell division cycle 7 (Cdc7) silencing were done using specific small interfering RNA. Transit
or stable inducible overexpression of these proteins and casein kinase Iε (CKIε) were also used, as well as several
pharmacological inhibitors that target TopoIIa, Cdc7 or CKIε. We manipulated HME cells that expressed H2B-GFP,
or did not, to detect chromosome bridges. Immunoprecipitation and direct Western blot analysis were used to
detect interactions between these proteins and their total expression, respectively, whereas interactions on
chromosomal arms were detected using a trapped in agarose DNA immunostaining assay. TopoIIa
phosphorylation by Cdc7 or CKIε was done using an in vitro kinase assay. The TopoGen decatenation kit was used
to measure TopoIIa decatenation activity. Finally, a comet assay and metaphase chromosome spread were used to
detect chromosome breakage and changes in chromosome condensation or numbers, respectively.
Results: We found that geminin and TopoIIa interact primarily in G2/M/early G1 cells on chromosomes, that
geminin recruits TopoIIa to chromosomal decatenation sites or vice versa and that geminin silencing in HME cells
triggers the formation of chromosome bridges by suppressing TopoIIa access to chromosomal arms. CKIε kinase
phosphorylates and positively regulates TopoIIa chromosome localization and function. CKIε kinase overexpression
or Cdc7 kinase silencing, which we show phosphorylates TopoIIa in vitro, restored DNA decatenation and
chromosome segregation in geminin-silenced cells before triggering cell death. In vivo, at normal concentration,
geminin recruits the deSUMOylating sentrin-specific proteases SENP1 and SENP2 enzymes to deSUMOylate
chromosome-bound TopoIIa and promote its release from chromosomes following completion of DNA
decatenation. In cells overexpressing geminin, premature departure of TopoIIa from chromosomes is thought to
be due to the fact that geminin recruits more of these deSUMOylating enzymes, or recruits them earlier, to bound
TopoIIa. This triggers premature release of TopoIIa from chromosomes, which we propose induces aneuploidy in
HME cells, since chromosome breakage generated through this mechanism were not sensed and/or repaired and
the cell cycle was not arrested. Expression of mitosis-inducing proteins such as cyclin A and cell division kinase 1
was also increased in these cells because of the overexpression of geminin.
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Geminin silencing induces a cytokinetic checkpoint in which Cdc7 phosphorylates TopoIIa and inhibits its
chromosomal recruitment and decatenation and/or segregation function. Geminin overexpression prematurely
deSUMOylates TopoIIa, triggering its premature departure from chromosomes and leading to chromosomal
abnormalities and the formation of aneuploid, drug-resistant cancer cells. On the basis of our findings, we propose
that therapeutic targeting of geminin is essential for improving the therapeutic potential of TopoIIa agents.
Introduction
In eukaryotes, the initiation of DNA replication involves
the formation and activation of the prereplication com-
plex (pre-RC) at the origins of replication (ORIs). The
pre-RCs are formed by the sequential binding of the
origin recognition complex (ORC1 to ORC6), cell divi-
sion cycle 6 (Cdc6), Cdt1 and minichromosome mainte-
nance (MCM2 to MCM7) proteins to DNA [1]. Since
loading of the MCM complex onto ORIs is the rate-
limiting step in DNA replication, its recruitment to
ORIs is inhibited by geminin, the only known endogen-
ous inhibitor of DNA replication. Thus, geminin level
and/or activity seem to control the assembly of pre-RCs
at ORIs and to determine whether the origins are
licensed [2-7].
Geminin, a multifunctional small protein (about 30
kDa), was first identified in a screen for proteins
degraded during mitosis using Xenopus egg extracts
[8-11]. Since then, however, roles for geminin during
mitosis have been described [12-20], arguing against its
mitotic degradation, at least in mammalian cells. More
precisely, geminin silencing in human mammary epithe-
lial (HME) cells [12] or mouse embryos [14], while
showing minimal effect on S-phase progression, comple-
tely blocked the progress through mitosis [12]. The
HME mitosis-arrested cells (due to geminin silencing)
showed increased expression and activity of cyclin B1,
checkpoint protein 1 (Chk1), and Cdc7 [12]. Surpris-
ingly, only Cdc7 cosilencing triggered apoptosis in gemi-
nin-silenced cells [12], implying that Cdc7 is the kinase
that maintains the cytokinetic checkpoint induced by
geminin silencing in HME cells [12].
The Cdc7-Dbf4 complex is essential for ORI firing
and maintenance of replication forks [21-26]. Cdc7 inac-
tivation in cancer cell lines causes growth arrest and cell
death, while only arresting growth in normal cells [27].
Although the mechanism of cancer-specific cell death is
not yet defined, it is possible that insufficient levels of
Cdc7 during cell division may result in stalled and
incomplete replication forks, induction of genetic
instability and cell death by entering aberrant mitosis in
a p53-independent manner [28-30].
Topoisomerases (Topo) are multifunctional enzymes
that resolve topological chromosomal complexities, such
as knots, tangles and catenanes, arising during DNA
metabolism [31]. Yeasts and Drosophila cells contain a
single type II Topo (TopoII), whereas mammalian cells
possess two TopoII isoforms, a and b (TopoIIa and
TopoIIb). Both enzymes can facilitate transcription and
replication of chromatin templates [32,33]. However,
only TopoIIa is absolutely required for DNA decatena-
tion and chromatid separation during anaphase [34,35].
During DNA decatenation, TopoIIa dimer binds a
DNA helix and hydrolyzes adenosine triphosphate
(ATP) to introduce a transient double-stranded break
(DSB) through which it passes the other entangled
intact helix. Then the DNA DSB is religated, and
TopoIIa dissociates from the DNA [32-35]. Further-
more, TopoIIa binding to chromosomes and its decate-
nation activity are modified by phosphorylation and
SUMOylation [36-39]. For example, casein kinase Iε
(CKIε) phosphorylates TopoIIa on serine 1106 (S1106)
in G2/M cells and induces the TopoIIa chromosome
localization and decatenation function as well as sensi-
tivity to TopoIIa-targeting drugs [40-42]. Moreover, the
complex RAN binding protein 2/ubiquitin-conjugating
enzyme 9 (RanBP2/Ubc9) SUMOylates TopoIIa and
triggers its chromosome translocation and decatenation
activity [39].
TopoIIa’s ability to cleave DNA in a reversible man-
ner makes it an ideal target for agents such as doxorubi-
cin and etoposide, which poison the enzyme via the
trapping of the transient reaction intermediate com-
posed of TopoIIa bound covalently to the 5′ end of the
cleaved DNA strands (cleavable complexes), preventing
religation of DNA [43]. It thus induces DNA damage,
genomic instability and cell death [42,44]. However,
development of resistance to these agents limits their
therapeutic use [45]. Therefore, an understanding of the
mechanisms that lead to the development of this resis-
tance is essential to the improvement of the therapeutic
potential of these agents.
In the present study, we show that geminin silencing
induces chromosome bridge formation by inhibiting
TopoIIa chromosome localization and function. Cdc7
cosilencing or CKIε overexpression in geminin-silenced
cells restored TopoIIa chromosomal localization and
prevented the formation of chromosome bridges. This
finding suggests that CKIε is a positive regulator and
Cdc7 is a negative regulator of TopoIIa chromosomal
Gardner et al. Breast Cancer Research 2011, 13:R53
http://breast-cancer-research.com/content/13/3/R53
Page 2 of 20localization and function. However, these cells under-
went apoptotic cell death, suggesting that they were
unprepared to enter G1.M o r e o v e r ,g e m i n i na n d
TopoIIa interact on chromosomes in G2/M/early G1
cells, and geminin overexpression prematurely releases
TopoIIa from chromosomes, in part by enhancing
TopoIIa deSUMOylation on chromosomes. Geminin
overexpression also inhibits DNA decatenation before
the religation step, leading to linearization of model
entangled DNA in vitro and chromosome breakage and
aneuploidy in vivo. These effects were accompanied by
decreased cytotoxicity to TopoIIa inhibitors. Impor-
tantly, Cdc7 co-overexpression corrected both defects.
These data represent a potential mechanism for
TopoIIa drug resistance and suggest that inhibiting the
activity of geminin and TopoIIa,C K I ε and/or Cdc7 can
be more beneficial for breast cancer patients with
aggressive, drug-resistant disease.
Materials and methods
Cell culture and drug treatments
All cells were cultivated in RPMI 1640 Medium (Gibco,
Grand Island, NY, USA) containing 10% fetal bovine
serum (FBS) (Gemini Laboratories, Inc, West Sacra-
mento, CA, USA) at 37°C in a 10% CO2-containing
atmosphere unless otherwise mentioned, except HME
cells that were maintained in growth factor-supplemen-
ted Dulbecco’s modified Eagle’sm e d i u m / H a m ’sF - 1 2
mammary epithelium basal medium (MEBM) (Clo-
netics/Cambrex, Walkersville, MD, USA). For fluores-
cence-activated cell sorting (FACS) analysis, treated cells
were fixed in 100% ethanol, stained with 2.5 μg/mL pro-
pidium iodide (PI) (Sigma, St. Louis, MO, USA), supple-
mented with RNase A and incubated at 37°C for one or
two hours. A HME cell line that carries a pBOS-H2B
plasmid (Clontech Laboratories, Mountain View, CA,
USA) was generated by standard plasmid transfection,
and clones were selected with blastocidin (Sigma). Eto-
poside, doxorubicin and IC261 were obtained from
Sigma, ICRF187 and PHA767491 were purchased from
Tocris Bioscienc (Ellisville, Missouri, USA) and ICRF193
was obtained from Funakoshi (Tokyo, Japan). All drugs
were dissolved in dimethyl sulfoxide (DMSO).
Geminin cloning and bacterial expression
The protocol described by Nakuci et al. [12] was used.
In brief, geminin full-length cDNA was amplified from
IMR90 total RNA using the following primers cut with
BamHI/SalI and ligated to the glutathione S-transferase
(GST) vector pGEX-4T2 cut with the same enzymes:
forward 5′-CGGGATCCATGAATCCCAGTATGAAG
CAGAAACAAGAA-3′ and reverse 5′-ACGCGTC
GACTCATATACATGGCTTTGCATCCGTA-3′.T h e
GST-fused geminin was expressed in competent bacteria
One Shot BL21 Star (DE3)pLysS (Invitrogen, Carlsbad,
CA, USA), induced with isopropyl-b-D-thiogalactoside
and purified on Glutathione Sepharose™ 4B beads (GE
healthcare, Piscataway, NJ, USA) and eluted from the
beads using 10 mM glutathione in 50 mM Tris HCl, pH
8.0. Using a similar strategy, geminin full-length cDNA
was also ligated to the retrovirus plasmid Rev-Tre
(Clontech), and the retrovirus was prepared and used to
infect the HME cell line expressing the inducer pTet-
ON (Clontech). Geminin clones were generated by
appropriate selection.
Antibodies
Mouse anti-geminin antibody (Ab) generation was
described earlier [12]. We used mAbs a-cyclin A1, anti-
cyclin E, anti-cyclin B1 and anti-CKIε (610445; BD
Transduction Laboratories (San Jose, CA, USA); mAb
a-actin (Ab-1; Oncogene Science, Cambridge, MA,
USA); rAb a- C d k 2( P h a r m i n g e n ,S a nJ o s e ,C A ,U S A ) ;
rAb a-pChk1 (Cell Signaling Technology, Danvers, MA,
USA); mAb a-cdc7 (MS-1888-P; NeoMarkers, Fremont,
CA, USA); mAb a-cdc2 (B-6), anti-Chk1 (G-4), rAb a-
Sp1 (H-225), anti-geminin (FL- 209) and gAb a-lamin B
(C-20, sc-6216) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA); rAb a-H2B (ab18977) and mAb a-TopoIIa
(ab52934) (Abcam, Cambridge, MA, USA); and rAb a-
CKII (Millipore, Danvers, Massachusetts:, USA).
Cell synchronization and small interfering RNA
transfection
HME cells were incubated in growth factor-free medium
for 72 hours to produce cells in G0/G1 phase (> 95%)
[12]. G0/G1 cells were then released from arrest in med-
ium containing growth factors, and 16 hours (S phase),
22 hours (G2/M phase) or 24 hours (M/G1 phase) later
cells were collected and analyzed. HME cell synchroni-
zation and transfection were performed as described by
ElShamy and Livingston [46]. In brief, cells were trans-
fected (0 hours) in serum-free medium with a relevant
double-stranded RNA interference reagent by a standard
method using oligofectamine. At 24 hours, the medium
was changed, and growth factor-containing MEBM (Clo-
netics/Cambrex) was added. Small interfering RNA
( s i R N A )u s e dw e r es i G e m :T G A G C T G T C C G C A G
GCTTT, scrambled siGem: TGATTTGTCCGCAGC
TGGC, siCdc7: TTTGTGAACACCTTTCCTGTT and
siTopoIIa: sc-36695 (Santa Cruz Biotechnology). The
silenced luciferase (siLuc) and silenced green fluores-
cence protein (siGFP) used were from previously pub-
lished data.
Kinase assay
Cells were collected by trypsinization and washed twice
with phosphate-buffered saline (PBS). Whole cell extract
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Tris HCl, pH 8.0, 0.5% Nonidet P-40 (NP-40) and 120
mM NaCl) at 4°C for 30 minutes and centrifuged at
high speed for 15 minutes. Protein A beads were added
to the supernatant along with antibodies (anti-Sp1, anti-
CKIε or anti-Cdc7) for 2 to 2.5 hours. Beads were
washed once with NETN lysis buffer containing 250
mM NaCl, twice with NETN containing 150 mM NaCl
and once with kinase buffer (50 mM Tris HCl, pH 7.5,
10 mM MgCl2 and 1 mM dithiothreitol (DTT), added
fresh). Twenty microliters of kinase buffer were added
to the beads, along with 7 μLo fA T Pm i x( 5μLf r o m
40 μMc o l dA T P+2μLo fr a d i o a c t i v eA T P( 2 0μCi))
and 10 or 100 ng of purified TopoIIa (TopoGen,
Columbus, OH, USA). The reaction was rocked at room
temperature for 45 minutes and then stopped by adding
20 μL of sodium dodecyl sulfate (SDS) loading buffer
and boiling for 10 minutes.
Cell sonication, chromatin purification, Western blot
analysis and immunoprecipitation
The protocols used by Nakuci et al. [12] and ElShamy
and Livingston [46] were used to isolate total extracts
by sonication and chromatin preparations. Briefly, cells
at about 75% confluence were washed several times with
PBS and trypsinized. After being washed, 1 × 10
7 cells
were resuspended in 1 mL of Buffer A (110 mM
KC2H3O2,1 5m MN a C 2H3O2,2m MM g C 2H3O2,0 . 5
mM ethylene glycol tetraacetic acid and 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
pH 7.3). Next, we added 2 mM DTT and 50 μg/mL
digotinin to the cell suspension. The cells were agitated
at 4°C for 10 minutes. Nuclei were pelleted by centrifu-
gation in a swinging bucket rotor at 1,500 × g for 10
minutes. They were resuspended in hypotonic Buffer B
(1 mM HEPES, pH 7.5, and 0.5 mM ethylenediaminete-
traacetic acid (EDTA) supplemented with 0.5% NP-40).
Typically, a nuclear pellet of about 50 μL was resus-
pended in 0.5 mL of Buffer B. The nuclear suspension
was then agitated at 4°C for 15 minutes and layered on
top of a 10-mL sucrose cushion (100 mM sucrose, 0.5
mM Tris HCl, pH 8.5), then centrifuged at 3,500 × g for
15 minutes at 4°C. The chromatin pallet was suspended
in 0.25 mM EDTA, pH 8.0, and sonicated three times
for 10 seconds each, each time using a Fisher Scientific
Model 100 Sonic Dimembrator (Fisher Scientific, Pitts-
burgh, PA, USA). After sonication, the chromatin sus-
pension was centrifuged twice at high speed for 10
minutes at 4°C, and the supernatants were retained.
This chromatin extract was first precleared by agitation
f o r2h o u r sa t4 ° Ci nt h ep r e s e n c eo f5 0μgo fp r o t e i n
A/G Sepharose beads, followed by pelleting of the
beads. The supernatant protein concentration was mea-
sured, and 500 μg of chromatin protein were routinely
immunoprecipitated using 1 or 2 μgo fA ba n d5 0μLo f
protein A/G Sepharose beads in a total volume of 1 mL
of NETN buffer (in which the NaCl concentration was
preset at 250 to 500 mM). In some experiments, the
deSUMOylation inhibitor N-ethylmaleimide (10 nM)
was added to sonicates.
Immunofluorescence analysis
Cells were seeded on slide chambers (LabTek, Roche-
ster, NY, USA) at 25% confluence 24 hours prior to pro-
cessing. Cells were fixed with 4% paraformaldehyde for
10 minutes at room temperature, permeabilized in Tri-
ton X-100 buffer (0.5% Triton X-100 in 20 mM HEPES,
pH 7.4, 50 mM NaCl, 3 mM Mg2Cl and 300 mM
sucrose containing 0.5% bovine serum albumin (BSA))
for 10 minutes at 4°C. Cells were then incubated for 30
minutes with 5% normal mouse or rabbit serum (MS or
RS) in PBS and then incubated for 30 minutes at 37°C
with primary antibody. Cells were then incubated with
appropriate fluorescein isothiocyanate- or rhodamine-
conjugated secondary antibodies diluted 1:5,000 to
1:10,000 in 5% MS or RS in PBS for 30 minutes at 37°C.
Coverslips were then mounted in anti-fade solution
(Vector Laboratories, Burlingame, CA, USA) supplemen-
ted with 4′6-diamidino-2-phenylindole (DAPI).
Comet assay
A neutral comet assay was performed to detect DSBs.
After induction of geminin by 2 μg/mL doxycycline
(Dox) for 72 hours, cells embedded in agarose were
lysed and subjected to electrophoresis as described pre-
viously [47]. Individual cells stained with 0.5 μg/mL
DAPI were viewed using an ultraviolet (UV) light fluor-
escence microscope (Olympus, San-Diego, CA, USA).
Quantification was achieved by analyzing x randomly
selected comets per slide with Komet 5.5 software
(Kinetic Imaging, Bath, UK) using the variable Olive
Tail Moment (with results measured in arbitrary units,
defined as the product of the percentage of DNA in the
tail multiplied by the tail length).
Trapped in agarose immunostaining assay
A 50-μL quantity of cell suspension medium warmed to
37°C was mixed with an equal volume of agarose solu-
tion (2% (wt/vol) in PBS, SeaPrep Agarose ultralow gel-
ling; FMC BioProducts, Rockland, ME, USA), which had
b e e nm e l t e da n dk e p ta t3 7 ° C .T h em i x t u r ew a si m m e -
diately spread evenly across a microscope slide and
quickly gelled by placing the slides onto a cold surface
(0°C). Slides were lysed for 15 minutes at 20°C in a buf-
fer containing 1% (wt/vol) SDS, 80 mM phosphate buf-
fer, pH 6.8, 10 mM EDTA and a protease inhibitor
mixture (final concentrations 2 μg/mL pepstatin A, 2
μg/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride,
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immersed in 1 M NaCl supplemented with the protease
inhibitor mixture for 30 minutes at 20°C, then washed
by immersion three times (5 minutes per wash) in PBS.
Immunofluorescence was performed according to a pro-
tocol described earlier [12]. Slides were counterstained
with Hoechst 33258 blue (10 μMi nP B S ;S i g m a )f o r5
minutes before application of coverslips that were
secured with a sealant.
TopoGen decatenation assay
TopoIIa e n z y m a t i ca c t i v i t yw a sa s s a y e db ym e a s u r i n g
the decatenation of kinetoplast (k)-DNA (TopoGen). A
standard assay carried out in a total volume of 20 μL
included 50 mM Tris HCl, pH 7.9, 88 mM KCl, 10 mM
MgCl2, 0.5 mM EDTA, 10 mM ATP, 10 mM DTT, 100
μg/mL BSA and 300 ng of k-DNA. The reaction mixture
containing TopoIIa immunoprecipitated from control
or siRNA-treated cells was incubated at 37°C, and the
reaction was stopped by the addition of 5 μLo fs t o p
solution (5% SDS, 25% Ficoll and 0.05% bromophenol
blue). The samples were resolved by electrophoresis at
115 V using a 1% agarose gel in Tris-acetate-EDTA buf-
fer with 0.5 μg/mL ethidium bromide and photographed
under UV illumination.
Relaxation of pBR322 plasmid negative supercoiled assay
The reactions were carried out by incubating 150 ng of
supercoiled pBR322 plasmid DNA at 37°C in 15 μLo f
reaction buffer (10 mM Tris HCl, pH 7.4, 5 mM MgCl2,
100 mM KCl and 0.5 mM ATP) and were initiated by
the addition of TopoII (1 or 2 U; TopoGen) and differ-
ent concentrations of GST-geminin as indicated or 100
ng of GST alone (control). Reactions were stopped by
the addition of 5 μL of loading buffer, and samples were
electrophoresed in 1% agarose gel in Tris-Borate-EDTA
(TBE) buffer (pH 8.0) at 10 V/cm for 4 hours. The gel
was then stained with TBE containing ethidium bromide
(0.5 μg/mL) for 10 minutes, washed extensively and
photographed.
Metaphase spread
Colcemid (100 ng/mL) was added directly to the culture
dish and swirled and incubated for 1 hour. Following
incubation, cells were trypsinized and washed with PBS.
After the cells were washed, all excess PBS was removed
and cells were gently resuspended in the residual PBS.
KCl (0.075 M) was added slowly dropwise to a quantity
of 10 mL to the cells resuspended in PBS. The reaction
was incubated at 37°C (in a water bath) for 5 to 10 min-
utes. The reaction was centrifuged at 900 rpm for 5
minutes, followed by removal of as much KCl as possi-
ble, and then the cells were gently resuspended in the
residual PBS. Five milliliters of freshly prepared fixative
(3:1 methanol to acetic acid) were then added dropwise
to the cells and carefully mixed. After centrifugation of
the reaction at 900 rpm for 5 minutes and removal of
the fixative solution, the whole step was repeated with 2
mL of fixative. Finally, after removing all but 300 μLo f
the fixative, the cell mixture was dropped from about 18
inches onto an angled, humidified microscope slide and
air-dried for at least 10 minutes. Next, PI or Giemsa
stain was used to stain the chromosome spread.
MTT and activated caspases 3 and 7 assays
MTT and activated caspases 3 and 7 assays were done
using the CellTiter 96 AQueous One Solution Cell Prolif-
eration Assay (G3580; Promega, Madison, WI, USA) or
the Caspase-Glo 3/7 Assay (G8091; Promega), respec-
tively, according to the manufacturer’s instructions.
Measurements were obtained using optical density at
490 nm. Each experiment was done in eight samples,
and the whole experiment was repeated three times.
Cell cycle analysis
Cell cycle analysis was carried out by flow cytometery
after PI staining using a standard protocol.
Statistical analysis
Comparisons of treatment outcomes were tested for sta-
tistically significant differences using Student’s t-test for
paired data. Statistical significance was assumed at *P ≤
0.05, **P ≤ 0.01 and ***P ≤ 0.001.
Results
Geminin silencing promotes formation of chromosome
bridges in HME cells
We recently showed that geminin silencing promotes
mitotic arrest in HME cells [12]. To elucidate the
mechanism whereby this occurs, we generated an HME
cell line that carried a histone 2B fused to green fluores-
cence protein (H2B-GFP) cDNA. Unlike control siLuc-
treated cells, geminin silencing induced anaphase (com-
pare Figures 1C and 1C′ to Figures 1A and 1A′) or telo-
phase (compare Figures 1D and 1D′ to Figures 1B and
1B′) chromosome bridges in these cells. Previous studies
showed that inhibiting the expression or activity of
TopoIIa also promotes the formation of chromosome
bridges [48,49]. Indeed, TopoIIa silencing in this HME/
H2B-GFP cell line also induced anaphase (Figures 1E
and 1E′) or telophase (Figures 1F and 1F′) chromosome
bridge formation. Similar data were obtained in HME
cells treated in the same manner and stained with DAPI
(see Additional files 1A to 1C). This suggests that, like
TopoIIa, geminin is required for proper chromosome
segregation and that the lack of proper chromosome
segregation is what arrests geminin-silenced cells in
mitosis [12].
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HME cells
To evaluate whether geminin and TopoIIa interact,
HME cells synchronized in different parts of the cell
cycle (Additional file 2) were sonicated to isolate all cel-
lular proteins, including those on the chromatin. Total
cellular proteins were then immunoprecipitated with
anti-Cdc7-, anti-geminin-, anti-Sp1 (negative control)-
or anti-TopoIIa-specific antibodies. In HME cells, Cdc7,
geminin, Sp1 and TopoIIa are all present in all phases
of the cell cycle (Figure 2A). The highest level of gemi-
nin was observed in G2/M cells (Figure 2A), while the
lowest level of TopoIIa was observed in G0/G1 cells
(Figure 2A). Cdc7 and Sp1 expression did not change
throughout the cell cycle (Figure 2A).
Furthermore, neither Cdc7 nor Sp1 antibodies coimmu-
noprecipitated geminin or TopoIIa (Figure 2A), and
Cdc7 and Sp1 were not coimmunoprecipitated by anti-
geminin or anti-TopoIIa antibodies (Figure 2A). Mean-
while, anti-geminin antibody coimmunoprecipitated
TopoIIa and anti-TopoIIa antibody coimmunoprecipi-
tated geminin specifically from G2/M and M/G1 cells
(Figure 2A). These data suggest that geminin and
TopoIIa form a complex in G2/M/early G1 cells, to
which Cdc7 is not recruited.
Geminin interacts with TopoIIa on chromosomes in HME
cells
To evaluate whether a geminin-TopoIIa interaction
occurs on chromosomes, we employed the trapped in
agarose DNA immunostaining (TARDIS) assay, which
detects TopoIIa on chromosomal arms [47]. HME cells
that had been exposed to 10 μM etoposide for 16 hours
(to stabilize TopoIIa cleavable complexes) were
embedded in agarose-covered microscope slides and
lysed to remove cell membrane and soluble proteins.
After washing the cells with high salt buffer (1 M NaCl)
to remove all noncovalently bound nuclear proteins, the
remaining chromosome-protein complexes were studied
by using immunofluorescence and Hoechst 33258 blue
dye DNA staining.
In control siLuc-treated cells, > 90% of the Hoechst
33258 blue-stained chromosomes were TopoIIa-a n d
geminin-positive (see Figure 2B, 1 to 3, and red and black
bars in Figure 2C). Importantly, the same spots on chro-
mosomes that stained for TopoIIa were clearly stained
for geminin (Additional file 3A). Although the Cdc7 level
rose in geminin-silenced cells (Additional files 3B and
3C), Hoechst 33258 blue-stained TopoIIa- or geminin-
positive chromosomes were Cdc7-negative (see Figure
2B, 4 to 6, and Figure 2B, 7 to 9, respectively, as well as
w h i t eb a r si nF i g u r e2 C ) .S u r p r isingly, geminin silencing
abolished TopoIIa chromosome recruitment (Figure 2B,
10, and Figure 2C). Similarly, in TopoIIa-silenced cells,
geminin was absent from chromosomes (Figure 2B, 13,
and Figure 2C). Since TopoIIa expression was not
affected in geminin-silenced cells and vice versa (Addi-
tional file 3C), these data suggest that geminin and
TopoIIa stabilize each other on chromosomes.
Although Cdc7 silencing did not affect TopoIIa or
geminin chromosome recruitment (Figure 2C), its cosi-
lencing restored TopoIIa recruitment to chromosomes
in geminin-silenced cells (Figure 2B, 11, and Figure 2C),
but not geminin recruitment to chromosomes in
TopoIIa-silenced cells (Figure 2B, 14, and Figure 2C).
These data suggest that Cdc7 upregulation in geminin-
silenced cells exerts negative regulation on TopoIIa
chromosome localization, perhaps by phosphorylation.
In support of this interpretation, the transit overexpres-
sion of the positive regulator CKIε that phosphorylates
TopoIIa restored the recruitment of TopoIIa to chro-
mosomes in geminin-silenced cells (Figure 2B, 12, and
Figure 2C) and not the recruitment of geminin to chro-
mosomes in TopoIIa-silenced cells (Figure 2B, 15, and
Figure 2C). Taken together, this information suggests
that geminin is required for TopoIIa recruitment to
chromosomes and that, while CKIε is an upstream posi-
tive regulator of TopoIIa chromosome recruitment,
Cdc7 is an upstream negative regulator of TopoIIa
chromosome recruitment.
Cdc7 phosphorylates TopoIIa in vitro
To evaluate whether the serine kinase Cdc7 [50] indeed
phosphorylates TopoIIa, we used an in vitro kinase assay.
Figure 1 Geminin silencing induces chromosome bridges.
Human mammary epithelial cell/histone 2B fused to green
fluorescence protein (HME/H2B-GFP) protein is an HME cell line that
carries an H2B-GFP allele. Examples of live HME/H2B-GFP cells in
anaphase (A and A′, C and C′ and E and E′) or telophase (B and
B′, D and D′ and F and F′) 72 hours following luciferase control
silencing (siLuc) (A and B′), geminin silencing (siGem) (C and D′) or
topoisomerase IIa silencing (siTopoIIa) (E and F′). Arrows indicate
chromosome bridges.
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was incubated with protein A beads coupled to anti-Cdc7,
anti-CKIε or anti-Sp1 (negative control) antibodies.
Immunoprecipitated proteins were then incubated for 30
minutes with 100 or 10 ng of purified TopoIIa (TopoGen)
in the presence of radioactive ATP. While mock and Sp1
immunoprecipitates did not phosphorylate TopoIIa in
this assay (Figure 2D), Cdc7 phosphorylated the 100 ng
quantity, and CKIε phosphorylated the 100 and 10 ng
quantities, of purified TopoIIa protein (Figure 2D). These
data suggest that Cdc7 indeed phosphorylates TopoIIa,a t
least in vitro.
Cdc7 is upregulated in geminin-silenced cells to enforce
the mitotic checkpoint induced in these cells
Neither Cdc7 silencing nor CKIε overexpression affected
chromosome segregation in control (siLuc) HME/GFP-
H2B cells (Figure 3A, 1 and 2, and Figure 3A, 7 and 8,
Figure 2 Geminin interacts with TopoIIa on chromosomes in HME cells. (A) HME cells synchronized in G0/G1,S ,G 2/M and M/G1 were
sonicated and immunoprecipitated with the indicated antibodies, followed by immunoblotting with the indicated antibodies. (B) HME cells
treated with etoposide (10 μM, overnight) were then collected and processed for analysis using trapped in agarose DNA immunostaining
(TARDIS) assay. Shown are examples of cells costained with Hoechst 33258 blue, TopoIIa and geminin antibodies (1 to 3), costained with
Hoechst 33258 blue, TopoIIa but not Cdc7 antibodies (4 to 6) or costained with Hoechst 33258 blue, geminin but not Cdc7 antibodies (7 to 9).
Geminin-silenced HME cells (10), plus cell division cycle 7 silencing (siCdc7) (11) or plus casein kinase Iε (CKIε) overexpression (12) are shown.
TopoIIa-silenced HME cells (13) plus Cdc7-silenced (14) or plus CKIε overexpression (15) are also shown. (C) Quantification of cells costained with
Hoechst 33258 blue and Cdc7 (white bars), geminin (red bars) or TopoIIa (black bars) in TARDIS assays 72 hours after control, Cdc7, geminin,
TopoIIa, geminin silencing and Cdc7 silencing (or CKIε overexpression); geminin and TopoIIa silencing; or TopoIIa silencing and Cdc7 silencing
(or CKIε overexpression). Values presented are means ± SD. **P ≤ 0.01. (D) In vitro kinase assay performed on purified TopoIIa using CKIε or
Cdc7 immunoprecipitated from HME cells.
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files 1D and 1G, respectively). Geminin but not TopoIIa
silencing increased Cdc7 and decreased CKIε expression
(Additional files 3B and 3C and data not shown). Cdc7
silencing or CKIε overexpression in geminin-silenced
cells restored chromosome segregation stalled in gemi-
nin- and not in TopoIIa-silenced HME cells expressing
H2B-GFP (Figure 3A, 3 to 6, and Figure 3A, 9 to 12,
respectively, and Figure 3B) or in HME cells (Additional
files 1E through 1H and Additional files 1F through 1I,
respectively). These data reinforce the view that CKIε is
a positive regulator and Cdc7 is a negative regulator of
TopoIIa chromosome localization and segregation
function.
Geminin [12], TopoIIa [34,35] and Cdc7 silencing or
CKIε overexpression had minimal effects on S-phase
progression or DNA replication based on cell cycle and
bromodeoxyuridine incorporation analysis (data not
shown). Moreover, while Cdc7 silencing or CKIε overex-
pression did not block cells from existing mitosis, gemi-
nin or TopoIIa silencing did (see low expression of
mitotic proteins in geminin-silenced cells in Additional
file 3B and [12]), which can explain why these treat-
ments had no effect on HME cell viability or cell death
(Figure 3C). However, Cdc7 cosilencing or CKIε overex-
pression in geminin- and not TopoIIa-silenced cells
reduced cell viability and induced cell death (Figure 3C).
These data suggest that restoring TopoIIa localization
and function by silencing of Cdc7 or overexpression of
CKIε in geminin-silenced and/or mitosis-arrested cells
induces cell cycle progression followed by cell death.
Presumably, cells are unprepared to complete mitosis,
perhaps because of the low expression of mitotic pro-
teins observed in these cells (see Additional file 3B and
Figure 3 Cdc7 silencing or CKIε overexpression restores chromosome decatenation in geminin-silenced cells and leads to cell death.
(A) Cdc7 silencing in control-silenced (1, 2), geminin (3, 4) or TopoIIa-silenced (5, 6) H2B-GFP HME cells, or CKIε overexpression in control (7, 8),
geminin (9, 10) or TopoIIa (11, 12) H2B-GFP HME cells. (B) Shown are the percentages of cells with anaphase or telophase chromosomal bridges
in cells that were control-silenced (n = 297, white bars), Cdc7-silenced (n = 284, yellow bars), geminin-silenced (n = 305, pink bars), geminin/
Cdc7-silenced (n = 310, light blue bars), geminin-silenced/CKIε-overexpressing (n = 291, medium blue), TopoIIa-silenced (n = 301, orange bars),
TopoIIa/Cdc7-silenced (n = 304, dark blue bars), TopoIIa-silenced/CKIε-overexpressing (n = 277, red bars), geminin/TopoIIa-silenced (n = 301,
black bars). Values presented are means ± SD. **P ≤ 0.01. (C) Shown are percentages of viable cells (white bars) or apoptotic cells (with high
caspase activity; black bars) following control, Cdc7, geminin, geminin/Cdc7, TopoIIa, TopoIIa/Cdc7 and geminin/TopoIIa silencing, as well as
geminin silencing/CKIε overexpression and TopoIIa silencing/CKIε overexpression, as well as geminin/TopoIIa silencing. Values presented are
means ± SD. **P ≤ 0.01.
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in geminin- and TopoIIa-silenced cells is due to the
activation of p53 in these G2/M-arrested cells. These
data put Cdc7, like CKIε, upstream of TopoIIa and
both Cdc7 and CKIε downstream of geminin with
regard to chromosome segregation and mitosis
progression.
Cdc7 upregulation in geminin-silenced cells suppresses
TopoIIa chromosome localization and decatenation
activity
Next we studied whether geminin is required for
TopoIIa decatenation activity. TopoIIa was immuno-
precipitated from the chromatin of HME cells silenced
from Cdc7, geminin or TopoIIa for 72 hours or exposed
to 10 μM doxorubicin or 10 μM etoposide (TopoIIa
inhibitors) for 24 hours. To confirm that chromatin-
bound TopoIIa was used in these experiments, immu-
noprecipitated proteins were digested with proteinase K
and the DNA was visualized on agarose gel (see Addi-
tional file 3D).
Protein A beads coupled to TopoIIa were then used
to decatenate entangled k-DNA in vitro using the Topo-
Gen decatenation kit. TopoIIa immunoprecipitated
from the control siLuc cells efficiently decatenated k-
DNA (see nicked circular (NCi-kD) and non-nicked cir-
cular (NNCi-kD) decatenated bands in Figure 4A, lanes
3 and 12). The intensity of these bands was measured
using ImageJ software (National Institutes of Health,
Bethesda, MD, USA) and taken as 100% (Figure 4B). As
expected, no TopoIIa could be immunoprecipitated
from the chromatin of TopoIIa-silenced cells (Figure
4B, inset) or TopoIIa-inhibited cells, and thus the
immunoprecipitates failed to decatenate k-DNA (Figure
4A, lanes 4, 10, 6 and 7, respectively, and Figure 4B).
Moreover, TopoIIa was localized to chromatin in Cdc7-
and not geminin-silenced cells (Figure 4B, inset). Thus
TopoIIa immunoprecipitated from the chromatin of
Cdc7-silenced cells efficiently decatenated k-DNA (Fig-
ure 4A, lane 11, and Figure 4B), whereas TopoIIa
immunoprecipitated from the chromatin of geminin-
silenced cells had minimal decatenation activity (Figure
4A, lanes 5 and 14, and Figure 4B). Importantly, Cdc7
silencing or CKIε overexpression in geminin-silenced
cells restored TopoIIa recruitment to chromatin (Figure
4B, inset) and the immunoprecipitated protein’s ability
to decatenate k-DNA (Figure 4A, lanes 13 and 15,
respectively, and Figure 4B). These data reinforce the
view that Cdc7 is a negative regulator, and CKIε is a
positive regulator, of TopoIIa chromatin localization
and decatenation activity.
High geminin level also inhibits TopoIIa decatenation
activity in vitro
Next, by using a TopoGen decatenation assay, we
sought to determine whether a high geminin level also
affects TopoIIa decatenation activity. GST alone (150
ng) was incubated with k-DNA in the absence or pre-
sence of 1 or 2 U of TopoIIa. No decatenation of k-
DNA was observed in the reactions containing no
TopoIIa (Figure 4C, lane 3). In the presence of 1 or 2 U
of purified TopoIIa, k-DNA was efficiently decatenated
(2 U > 1 U; Figure 4C, lanes 4 and 5). Next, different
concentrations of GST-geminin were added to the k-
DNA in the absence or presence of 1 or 2 U of purified
TopoIIa. In the absence of TopoIIa, we noticed that the
k-DNA was linearized by GST-geminin in a concentra-
tion-dependent manner (Figure 4C, lanes 6, 9, 12 and
15). When purified TopoIIa was added to these reac-
tions, decatenation (that is, cleavage and religation) of
the k-DNA was accomplished in reactions containing 10
and 50 ng of GST-geminin as evidenced by the reap-
pearance of NCi-kD and NNCi-kD (compare Figure 4C,
lanes 7 and 8 to lane 6, and lanes 10 and 11 to lane 9).
In the presence of 100 and 150 ng of GST-geminin,
however, TopoIIa completely lost its ability to religate
k-DNA as evidenced by the increased intensity of the
linearized bands and the decreased intensity of the deca-
tenated bands (Figure 4C, lanes 12 to 17). These data
suggest that, at higher concentrations, geminin prevents
the ligation ability of TopoIIa but has no effect on its
cleaving activity.
To ascertain that linearization of k-DNA by GST-
geminin is not entirely due to bacterial nuclease con-
taminates in this preparation, we incubated k-DNA with
2Uo fT o p o I I a alone or with GST-geminin or GST-
geminin previously incubated with anti-geminin anti-
body. TopoIIa completely decatenated the k-DNA (Fig-
ure 4C, lane 20). Adding 150 ng of GST-geminin to this
reaction again led to k-DNA linearization (Figure 4C,
lane 21). Importantly, when GST-geminin was first incu-
bated with excess anti-geminin monoclonal antibody
and then added to the reaction, almost complete
restoration of TopoIIa decatenation activity was
observed (Figure 4C, lane 22). Taken together, these
findings support the view that geminin possesses nucle-
ase activity, which is in line with our finding that, on a
Coomassie blue-stained gel, we could detect a band of
only about 25 kDa that corresponded to bacterial puri-
fied GST alone and a band of only about 55 kDa that
corresponded to GST-geminin (Additional file 3E).
However, several alternative explanations are described
in the discussion section below.
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negative supercoiling in vitro
As an alternative approach, we asked whether geminin
affects TopoIIa’s ability to resolve negative supercoiling
from the plasmid pBR322. In the absence of TopoIIa,
whether 100 ng of GST alone was or was not added to
the plasmid pBR322, the DNA appeared to be unaf-
fected as a supercoiled form (SCi-D)( F i g u r e4 D ,l a n e s
13 and 1, respectively). Surprisingly, however, adding 1
or 2 U of purified TopoIIa to the last reaction also was
unable to relax the plasmid pBP322 (see lack of the
relaxed (RCi-D)b a n di nF i g u r e4 D ,l a n e s2a n d3 ) .
When a low concentration of GST-geminin (10 ng) was
added, the DNA was converted into the nicked form
(NCi-D) as well as the linear form (L-D)( NCi-D >L-D;
Figure 4C, lane 4). Increasing the GST-geminin concen-
tration tilted the reaction toward the linear form (L-D
>NCi-D; see lanes 7 and 10 in Figure 4D).
I n t e r e s t i n g l y ,i nt h ep r e s e n c eo fT o p o I I a and GST-
geminin, the plasmid was relaxed, although the levels of
the relaxed form of pBP322 (RCi-D) decreased with
increasing concentrations of GST-geminin (Figure 4C,
compare lanes 11 and 12 to lanes 5 and 6 as well as to
lanes 8 and 9). At 2 U, TopoIIa was more efficient in
completing religation than at 1 U as measured by the
increase in the level of RCi-D and the decrease in L-D
Figure 4 Geminin at low or high concentrations prevents TopoIIa activity. (A) TopoIIa immunoprecipitated from the chromatin of HME
cells 72 hours after transfection with control, geminin, Cdc7 or TopoIIa small interfering RNA (siRNA) or 24 hours after doxorubicin (10 μM) or
etoposide (10 μM) treatment were used to decatenate kinetoplast (k)-DNA as a substrate using a TopoGen assay as described in Materials and
methods. NCi-kD indicates the position of nicked circular decatenated k-DNA minicircles and NNCi-kD indicates the position of non-nicked
circular decatenated k-DNA minicircles, while the catenated DNA networks are retained in the wells of the gel (C-kD). The markers are 1-kb DNA
ladder (lane 1) or linear and decatenated k-DNA (lanes 8 and 9). (B) Quantification of the reactions shown in (A). Values presented are means ±
SD. **P ≤ 0.01. Inset shows the expression of TopoIIa on chromatin (upper) or whole cell (lower) extracts. (C) A decatenation assay was carried
out using k-DNA as the substrate with 0, 1 or 2 U of purified TopoIIa in the presence of 150 ng of glutathione S-transferase (GST) alone or 10,
50, 100 or 150 ng of GST-geminin. The reactions on the right are decatenation reactions in the presence of 2 U of TopoIIa alone or with 150 ng
of GST-geminin or 150 ng of GST-geminin that was incubated earlier with an excess anti-geminin antibody. (D) Relaxation of supercoiled pBR233
DNA assay. The plasmid pBR233 was incubated with 0, 1 or 2 U of purified TopoIIa in the presence of 50 ng of GST alone or 0, 10, 50 or 100 ng
of GST-geminin as described in Materials and methods. SCi-D, RCi-D, L-D and NCi-D indicate the positions of supercoiled, relaxed, linear and
nicked circular pBR233 DNA.
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Figure 4C). These data suggest that a higher concentra-
tion of GST-geminin reduces TopoIIa’s ability to com-
plete the relaxation process and prevents the religation
of DNA. Several alternative models to explain these data
are described in the discussion section below. Taken
together, these observations reveal that geminin inhibits
TopoIIa decatenation and relaxation activity in a con-
centration-dependent manner, at least in vitro.
Geminin silencing prevents TopoIIa binding to
chromosomes in vivo
Compared to HME cells, geminin, TopoIIa,C d c 7a n d
CKIε proteins are overexpressed in several estrogen
receptor (ER)-positive breast cancer cell lines (for
example, MCF7 and BT474) as well as ER-negative
breast cancer cell lines (for example, MDAMB231,
MDAMB453 and SKBR3) (Figure 5A). The MDAMB231
cell line was chosen to perform the following experi-
ments. Low but detectable levels of TopoIIa were
immunoprecipitated from control (siLuc/DMSO)-treated
MDAMB231 cell chromatin (Figure 5B, lanes 1 and 7),
which efficiently decatenated k-DNA in the TopoGen
assay (taken as 100%; Figure 5C and Additional file 4
lanes 1 and 7). In contrast, although TopoIIa was
detected in whole cell extracts (sonicates) of geminin-
silenced MDAMB231 cells (that is, siGem/DMSO lanes
in Figure 5B, bottom panels), no detectable protein
could be immunoprecipitated from the chromatin of
these cells (Figure 5B, lanes 4 and 10), and these
Figure 5 Geminin overexpression inhibits TopoIIa chromatin localization and activity. (A) Expression of Cdc7, CKIε, geminin and TopoIIa
in several breast cancer cell lines. (B) Top: TopoIIa immunoprecipitated from the chromatin of MDAMB231 cells following Luc (control) or
geminin silencing for 72 hours and treatment with dimethyl sulfoxide (DMSO), etoposide (10 μM), PHA767491 (10 μM) or IC261 (10 μM) during
the last 24 hours. Bottom: TopoIIa and geminin from whole cell extracts of the treatments described above. (C) Quantification of decatenation
using k-DNA as the substrate by TopoIIa immunoprecipitated from the chromatin of MDAMB231 treated with the treatments indicated in (B).
Values presented are means ± SD. **P ≤ 0.01. (D) TopoIIa levels on the chromatin of HME or induced Gem9 (72 hours) following 24-hour
exposure to etoposide (etopo, 10 μM) and doxorubicin (doxo, 10 μM). (E) The effect of DMSO (none) or 10 μM etoposide, doxorubicin, ICRF-187
or ICRF-193 exposure for 24 hours on the viability of Gem9 cells grown in the presence or absence of doxycycline (2 μg/mL) and Cdc7 siRNA
(72 hours) or 10 μM PHA767491 (last 24 hours) as measured using the MTS assay.
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activity in the TopoGen assay (Figure 5C and Additional
file 4 lanes 4 and 9).
CKIε (already reduced in geminin-silenced cells; see
Additional file 5A) inactivation using the specific inhibi-
tor IC261 (10 μM) significantly decreased the level of
TopoIIa immunoprecipitated from the chromatin of
control (Figure 5B, lane 9) as well as geminin-silenced
(Figure 5B, lane 12) MDAMB231 cells. Both immuno-
precipitates failed completely to decatenate k-DNA (Fig-
ure 5C and Additional file 4 lanes 8 and 10). In
contrast, Cdc7 (expression increased in geminin-silenced
cells; Additional file 5A) inactivation using the specific
inhibitor PHA767491 (10 μM [27,51]) significantly
increased the level of TopoIIa immunoprecipitated from
the chromatin of control (siLuc)- and geminin-silenced
MDAMB231 cells (compare lanes 3 to 1 and 6 to 4,
respectively, in Figure 5B). Interestingly, the decatena-
tion activities of both immunoprecipitates were higher
than their corresponding DMSO-treated immunopreci-
pitates (Figure 5C; compare lanes 3 to 1 and 6 to 4 in
Additional file 4).
However, because it was proposed earlier that
PHA767491 could also target cell division kinase 9
(Cdk9), a kinase involved in the phosphorylation of
RNA polymerase II and in the transcriptional regulation
of gene expression [27,51-53], we investigated whether
gene expression is altered in HME and MDAMB231
cells treated with 10 μM PHA767491 for 24 hours by
using a reverse transcriptase polymerase chain reaction
assay. In both control and PHA767491-treated HME
cells, we detected similar levels of normal expression of
cell cycle regulators such as cyclin D1, A and B1;
growth factors such as epidermal growth factor and
basic fibroblast growth factor; cell surface receptors
such as epidermal growth factor receptor and human
epidermal growth factor receptor 2; and housekeeping
genes such as glyceraldehyde 3-phosphate dehydrogen-
ase, 18S and actin mRNA (Additional file 5B). Similar
results were obtained using MDAMB231 cells. Thus, we
concluded that, at least in HME or MDAMB231 cells,
the effect of PHA767491 on Cdk9 kinase is minimal.
Geminin overexpression reduces TopoIIa level on
chromosomes and induces etoposide resistance
A very low level of TopoIIa was immunoprecipitated
from the chromatin of control-treated MDAMB231 cells
that were exposed to 10 μMe t o p o s i d ef o r2 4h o u r s
(Figure 5B, lanes 2 and 8). This immunoprecipitate
showed only about 30% decatenation activity (Figure 5C
and Additional file 4, lane 2). Interestingly, a signifi-
cantly higher level of TopoIIa was immunoprecipitated
from the chromatin of geminin-silenced MDAMB231
cells (72 hours) that were exposed to 10 μM etoposide
during the preceding 24 hours (compare lane 5 to lane
2 and lane 11 to lane 8, respectively, in Figure 5B).
These immunoprecipitates showed significantly higher
decatenating activity (about 50%) (compare lane 5 to
lane 2 in Additional file 4; see also Figure 5C). These
data show that endogenous geminin overexpression in
breast cancer cell lines such as MDAMB231 prevents
the persistence of TopoIIa on chromosomes in a CKIε-
dependent (positively) and Cdc7-dependent (negatively)
manner, thus reducing the ability of the TopoIIa poison
(for example, etoposide) to covalently bind TopoIIa to
DNA. This action perhaps decreases these drugs’ killing
effect.
Indeed, geminin overexpression in Gem9 (HME cell
line inducibly (after Dox) overexpressing geminin) led to
low TopoIIa levels that could be detected on the chro-
matin following treatment of these cells with 10 μM eto-
poside or 10 μM doxorubicin as compared to control
HME cells treated the same way (Figure 5D). Further-
more, when uninduced Gem9 cells were exposed to 10
μM TopoIIa drugs (etoposide, doxorubicin, ICRF187 or
ICFR193) for 24 hours, their viability deceased by about
50% (Figure 5E). The same treatment had no effect on
induced Gem9 cells (Figure 5E), except when Cdc7
expression (using siRNA) or activity (using PHA767491)
was decreased, although only partially (Figure 5E).
These data suggest that geminin overexpression prema-
turely releases TopoIIa from chromosomes before these
drugs can induce binding to DNA. This leads to the fail-
ure of these drugs to poison the enzyme and thus sup-
presses their cellular toxicity. Suppressing Cdc7
expression or activity actually sensitized geminin-overex-
pressing cells to TopoIIa drugs, inducing cell death.
This is most likely due to the increasing level of
TopoIIa on chromatin (see Figure 5B).
Geminin overexpression triggers TopoIIa premature
deSUMOylation and release from chromosomes in vivo
To learn how geminin overexpression prematurely
releases TopoIIa from chromosomes, we looked for
modifications that target and/or release TopoIIa from
chromosomes. It was shown recently that TopoIIa
recruitment to chromosomes depends on its state of
SUMOylation by the complex RanBP2/Ubc9, while its
departure from chromosomes depends on its state of
deSUMOylation [39]. We reasoned that geminin overex-
pression perhaps affects TopoIIa SUMOylation and/or
deSUMOylation. Although increased levels of RanBP2,
Ubc9, Pan SUMO and TopoIIa were detected in
induced Gem9 cells compared to HME cells (Figure
6A), anti-TopoIIa antibody coimmunoprecipitated low
levels of RanBP2, Ubc9 and Pan SUMO from induced
Gem9 as compared to HME cells (Figure 6B, bottom
panels). Consistently, although more TopoIIa was
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to control cells (Figure 6B, top panels), the immunopre-
cipitated TopoIIa was not SUMOylated in these cells
(the blot was reprobed for Pan SUMO; see Figure 6B,
top panels).
To our knowledge, no specific deSUMOylating
enzyme has yet been identified for TopoIIa.T h es e n -
trin-specific proteases SENP1 and SENP2 are two deSU-
MOylating enzymes with a wide range of substrates
[54]. We first evaluated whether geminin interacts with
these enzymes. One milligram of HME or induced
Gem9 cell chromatin was immunoprecipitated using
anti-geminin or anti-Sp1 antibody. SENP1, SENP2 and
TopoIIa were coimmunoprecipitated with anti-geminin
antibody, but not anti-Sp1 antibody, from the chromatin
of HME and induced Gem9 (Figure 6C). Although the
expression levels of SENP1 and SENP2 were not chan-
ged by geminin overexpression (see Figure 6D), the level
of each enzyme immunoprecipitated with geminin anti-
body from induced Gem9 chromatin was much higher
than that immunoprecipitated from HME chromatin
(Figure 6C). Furthermore, the geminin-SENP1 complex
seems to form on the chromatin of G2,Ma n dM / G 1
cells (Figure 6E) and not on the chromatin of S cells
(Additional file 5D, left) in HME and Gem9 cells. In
contrast, a geminin-SENP2 complex seems to form on
the chromatin of M and M/G1 (Figure 6E) but not on
the chromatin of G2/M (Figure 6E) or S (Additional file
5D, left) of HME cells, whereas in induced Gem9 cells
the complex forms on G2/M, M and M/G1 cells (Figure
6E) but not on S cells (Additional file 5D). These inter-
actions seem to follow the expression of SENP1 and
SENP2 (Figure 6F and Additional file 5D, right). While
it is possible that the lack of SENP2 in these phases is
the reason for the lack of binding between geminin and
SENP2, at this moment the lack of binding between
geminin and SENP1 in the S phase is less obvious. It is
possible that the two proteins are differentially modified
in the G2/M/early G1 p h a s ei ns u c haw a yt h a ta l l o w s
them to bind each other that does not exist in the S
phase. Another possibility is that the two are separated
in space in the S phase but not in the G2/M/early G1
phase.
Importantly, while TopoIIa expression increased in
induced Gem9 cells in comparison to HME cells (Figure
6D), and while anti-TopoIIa antibody immunoprecipi-
tated more TopoIIa from induced Gem9 than HME cell
chromatin (Figure 6C, left), anti-TopoIIa did not coim-
munoprecipitate SENP1 or SENP2 from HME or
induced Gem9 (Figure 6C, left). Taken together, these
data show that while geminin binds SENP1 and SENP2
on the chromatin of HME cells and binds more of them
on the chromatin in induced Gem9, neither binds to
TopoIIa i nt h ep r e s e n c eo fe i t h e rn o r m a l( H M E )o r
overexpressed (induced Gem9) levels of geminin. These
data show that the low level of TopoIIa detected in eto-
poside- and doxorubicin-treated cells (see Figure 5D)
could be due to geminin overexpression-triggered pre-
mature TopoIIa deSUMOylation and departure from
chromosomes.
Geminin overexpression induces survival of DNA
damaged cells and leads to aneuploidy in HME cells
Two of the most dire consequences of premature release
of TopoIIa from chromosomes by overexpressed
Figure 6 Geminin overexpression promotes TopoIIa
deSUMOylation on chromosomes. (A) Expression in total cell
extracts of the indicated proteins in HME or induced Gem9 cells. (B)
Coimmunoprecipitates of the indicated proteins using anti-TopoIIa
antibodies from whole cell extracts. Top image shows reprobing of
the TopoIIa immunoprecipitate with anti-Pan SUMO antibody. (C)
Coimmunoprecipitates of the indicated proteins with anti-Sp1 or
anti-geminin antibodies (left) or TopoIIa (right) from the chromatin
of HME or induced Gem9 cells. (D) Expression of the indicated
proteins in HME or induced Gem9 cells (72 hours). (E)
Coimmunoprecipitates of the indicated proteins with anti-geminin
antibody from the chromatin of G2/M, M or M/G1 HME or induced
Gem9 cells (72 hours). (F) Expression of the indicated proteins in
whole cell extracts of G2/M, M or M/G1 HME or induced Gem9 cells
(72 hours). IP = immunoprecipitation; IB = immunoblotting.
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are (1) low efficacy of TopoIIa drugs, for example, dox-
orubicin or etoposide; and (2) production of damaged
chromosomes. Comet assays (natural) that measure
DNA tails (the hallmark of in vivo double-stranded
damaged chromosomes) were used to analyze whether
geminin overexpression indeed induces chromosomal
breakage by preventing TopoIIa-dependent religation
during the decatenation process.
While uninduced Gem9 cells showed no DNA tails in
this assay (Figure 7A, left, and Figure 7B), induced
Gem9 cells (72 hours) showed DNA tails (Figure 7A,
right and Figure 7B). Interestingly, overexpression of
Cdc7, but not CKIε, in induced Gem9 cells significantly
reduced DNA tail formation (Figure 7B). Of note in this
comet assay was that induced Gem9 showed DNA tails
in > 85% of the cells. Uninduced Gem9 showed DNA
tails in about 2% of the cells (Additional file 6A), and
Figure 7 Geminin overexpression promotes survival of DNA-damaged cells, leading to aneuploidy. (A) Comet assay performed using
Gem9 cells grown in the absence (left) or presence (right) of 2 μg/mL doxycycline (Dox) for 72 hours. (B) Quantification of the percentages of
cells with DNA tails in the comet assay shown in (A) in uninduced Gem9, induced Gem9 or induced Gem9 cells transfected with CKIε or Cdc7
cDNA. Values presented are means ± SD. **P ≤ 0.01. (C) Expression of cyclin A, cyclin B1, cell division kinase 1 (Cdk1), checkpoint protein 1
(Chk1), phosphorylated Chk1 (p-Chk1) and g-H2AX in Gem9 cells grown in the presence or absence of 2 μg/mL doxycycline for 72 hours. (D)
Percentage of G1,S ,G 2/M, tetraploid (> 4 N) and apoptotic (sub-G1) cells detected using fluorescence-activated cell sorting (FACS) analysis in
HME or uninduced or induced Gem9 cells. (E) Metaphase spread of uninduced (1 and 3) and induced (2 and 4) Gem9 cells for 1 or 7 days. (F)
Quantification of percentage of aneuploid cells after eight weeks in uninduced Gem9, induced Gem9 or induced Gem9 transfected with CKIε or
Cdc7 cDNA cells detected in metaphase spread analysis. Values presented are means ± SD. **P ≤ 0.01.
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cells showed DNA tails in 1% to 2% of the cells (Addi-
tional file 6A). These findings seem in line with the
notion that the DNA tails are due to damage induced
by TopoIIa’s premature release from chromosomes,
which occurs in geminin-overexpressing, but not gemi-
nin-silenced, cells. Accordingly, unlike control-treated
cells, geminin- and TopoIIa-silenced, but not Cdc7-
silenced, uninduced Gem9 cells were resistant to cell
death induced by TopoIIa drugs (Additional file 6B).
Taken together, these data show that geminin overex-
pression triggers DNA damage, most likely by triggering
premature release of TopoIIa from chromosomes before
it religates DNA.
Moreover, geminin overexpression suppressed the
expression and/or activation of the checkpoint protein
Chk1 (Figure 7C), as well as the DNA damage-sensing
and repair protein g-H2AX (Figure 7C) [55]. These data
indicate that while geminin overexpression promotes
DNA damage, the damage is not sensed or repaired and
the cell cycle is not arrested as would be the case in
cells with a normal level of geminin. Instead, geminin
overexpression accelerated the cycle as measured using
FACS analysis (Figure 7D). Since geminin-overexpres-
sing cells also show increased levels of mitosis-inducing
proteins, for example, cyclin A and Cdk1 (Figure 7C), it
would be expected that geminin-overexpressing cells,
although damaged, would continue to cycle. This could
explain, at least in part, the inability of TopoIIa drugs
to induce cell death in induced Gem9 (see Figure 5E)
and may imply that geminin overexpression triggers
chromosomal abnormalities such as aneuploidy.
Indeed, in our FACS analysis, we detected a high per-
centage of induced Gem9 cells with > 4 N DNA content
as compared to uninduced Gem9 (Figure 7D). More-
over, in analysis of metaphase chromosome spread
stained with Giemsa of uninduced, induced or induced
but transfected with Cdc7 or CKIε Gem9 cells, we
found that while < 1% of uninduced Gem9 cells were
aneuploid, while about 30% of induced Gem9 (for eight
weeks; that is, about 50 cell divisions) showed aneu-
ploidy. Interestingly, overexpression of Cdc7, but not
CKIε, significantly reduced the number of aneuploid
cells (Figure 7F).
Geminin overexpression inhibits TopoIIa activity in vivo
To evaluate whether geminin overexpression indeed
inactivates TopoIIa in vivo, we studied chromosome
condensation using metaphase spread. Uninduced or
induced Gem9 (for 1, 7 or 28 days) were treated for one
hour with the spindle microtubule depolymerizing drug
colcemid, followed by metaphase spread and PI staining.
While chromosome condensation was visualized under a
fluorescence microscope in uninduced and induced
Gem9 cells at 1 day (Figure 7E, lanes 1 and 2), at 7 days
(Figure 7E, lanes 3 and 4) and at 28 days (not shown),
induced Gem9 chromosomes were uncondensed (alter-
natively, decondensed; Figure 7E, 4), whereas uninduced
Gem9 chromosomes were still condensed (Figure 7E, 3).
These data suggest that geminin overexpression also
inactivates TopoIIa in vivo.
On the basis of all of these data, we propose that
geminin affects TopoIIa chromosome localization (see
TARDIS assay results in Additional file 6D) and activity
in a CKIε- and/or Cdc7-dependent manner and that its
overexpression induces the formation of aneuploid cells
(and does not induce chromosome bridges; see Addi-
tional file 6C) by prematurely releasing TopoIIa from
chromosomes after it cleaves DNA and before it reli-
gates it. These effects could contribute to the generation
of aggressive breast cancer cells that are resistant to
TopoIIa poison drugs.
Discussion
Chromosome decatenation and/or segregation and cell
division are coordinated in the cell cycle of all organ-
isms, from bacteria to humans. In human cells, TopoIIa
is involved in chromosome decatenation, condensation
and segregation [48]. Geminin’s binding to TopoIIa on
mitotic chromosomes and enhancing of its decatenation
activity clearly show that geminin’s physical and func-
tional interaction with TopoIIa is essential to coordinate
chromosome decatenation and/or segregation with cell
division. Considering geminin’s role in DNA replication,
it is possible to suggest that geminin stimulates TopoIIa
interaction and helps disentangle the freshly replicated
DNA. The negative supercoiling (unwinding) generated
at the initiation of replication at ORIs [56,57] and the
positive supercoiling (overwinding) generated ahead of
the replication fork during replication elongation
[58-61] must be resolved to facilitate strand separation.
It is possible that through the interaction of geminin
and TopoIIa, geminin loads onto or stabilizes TopoIIa
on chromosomes and thus increases the level of DNA-
bound TopoIIa and the effective rate of decatenation
and relaxation of the newly made sister duplexes [62,63].
Since chromosome condensation, alignment at the
metaphase plate and movement toward the poles [64]
occurred relatively normally in geminin-silenced cells
(Figure 1 and Additional file 1), the spindle and asso-
ciated molecular motors must function correctly in the
absence of geminin. Likewise, the normal attachment of
the chromosomes to the metaphase plate and lack of
checkpoint activation that monitors spindle tension [65]
in geminin-silenced cells suggest that kinetochores are
also unaffected by geminin silencing. It is thus possible
to propose that the primary function for the geminin-
TopoIIa complex is to resolve chromosome
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increase in the number and complexity of knotted repli-
cation bubbles would increase the number of nodes in
the catenane [56] that arrest segregation of the freshly
replicated DNA molecules [56], leading to chromosome
bridges and mitotic arrest [12,66]. Our present study
supports this proposition. Several proteins with wide
varieties of functions (such as the bacterial condensin-
like protein MukB [67], the Drosophila condensin pro-
tein Barren [68] and the bacterial SeqA protein that pre-
vents overinitiation of chromosome replication [69])
have been shown to function in a similar manner in
which they interact and/or stimulate the relaxation and
decatenation activities of TopoIIa (TopoIV in bacteria).
Similar to geminin silencing, mutations in these genes
prevent effective separation of sister chromatids during
anaphase because of the suppression of TopoIIa func-
tion. In future studies, it will be important to search for
other components in this geminin-TopoIIa complex
that regulate chromosome decatenation. This work will
be necessary to better understand the molecular
mechanism of proper decatenation/segregation during
mitosis.
One of the interesting and unexpected aspects of the
present study is the fact that GST-geminin could induce
linearization of k-DNA as well as pBP322 plasmid. As
mentioned above, we cannot rule out bacterial nuclease
contaminant in the GST-geminin preparation as the
source of the apparent DNA linearization in both assays.
However, while this might be possible in the pBP322
reaction, it is hard to imagine that this is the case in the
k-DNA reaction. The k-DNA used consisted of inter-
locked minicircles (mostly 2.5 kb) that form extremely
large networks of high molecular weight. Unless cut and
religated specifically by TopoIIa during the decatenation
process, these networks fail to enter the gel. Assuming
that a protein other than geminin cleaved the DNA, it
must have been pulled down specifically by GST-gemi-
nin and not by GST alone. This would make it a partner
and not contaminant. However, bacteria do not express
geminin. Therefore, a human homolog of this nuclease
must exist and would be worth cloning in the future.
Alternatively, it is possible that geminin at higher con-
centrations binds and masks a TopoIIa ligation-indu-
cing domain, if it exits. This could explain the fact that
only at much higher concentrations in these assays did
geminin prevent religation, but not cleaving activity, of
TopoIIa. Finally, it is possible that geminin itself has
nuclease activity. Geminin is a coiled-coil protein [70],
and many coiled-coil proteins, such as the Werner syn-
drome protein WRN [71], are known to have nuclease
activity. In support of the latter assumption, the fact
that incubating GST-geminin with anti-geminin anti-
body before the reaction restored TopoIIa’s ability to
decatenate the k-DNA (Figure 4C). At the moment, we
are unable to distinguish between these possibilities but
have future plans to investigate which is valid.
Phosphorylation of TopoIIa on S1106 is important in
TopoIIa translocation to chromosomes, DNA decatena-
tion, formation of drug-stabilized DNA cleavable com-
plex and modulation of drug sensitivity [40,41]. CKIε is
the only known kinase that targets this site in vitro and
in vivo [40,41]. The facts that CKIε overexpression
restored chromosome decatenation and/or segregation
that had stalled in the geminin-silenced cells and that
geminin overexpression upregulated CKIε expression
suggest a positive molecular link by which geminin con-
trols TopoIIa chromosome localization and function.
The facts that geminin overexpression decreased Cdc7
expression, that Cdc7 silencing restored stalled chromo-
some decatenation and/or segregation (that is, chromo-
some bridges) [72] in the geminin-silenced cells, that
Cdc7 overexpression reduced chromosome breakage
and aneuploidy induced by geminin overexpression and
that Cdc7 phosphorylated TopoIIa, at least in vitro, sug-
gest that Cdc7 is a negative molecular link between
geminin and TopoIIa chromosome localization and
function. It will be important in future studies to inves-
tigate whether Cdc7 also phosphorylates TopoIIa in
vivo and on which sites, what are the upstream kinases
and/or conditions that activate Cdc7 to phosphorylate
TopoIIa and what is their relation to geminin.
TopoIIa SUMOylation is inhibited and/or decreased in
geminin-overexpressing cells. It is possible that geminin
overexpression prevents TopoIIa SUMOylation by
decreasing its binding to the SUMOylating complex
RanBP2/Ubc9. Alternatively, it is possible that in normal
cells, one function of geminin is to bind and/or recruit the
deSUMOylating enzymes SENP1 and SENP2 to chromo-
somally bound TopoIIa and to facilitate its deSUMOyla-
tion and release from chromosomes after chromosome
decatenation is completed. In geminin-overexpressing
cells, this could be accelerated by the fact that geminin
recruits more of the enzymes and/or recruits them earlier
to TopoIIa, thus leading to premature deSUMOylation
and release of TopoIIa from chromosomes before the liga-
tion step. It is also possible that this is simply the result of
a dominant negative effect exerted by overexpressed gemi-
nin. Whatever the reason is, this could contribute to the
generation of DNA damage and low efficiency of
TopoIIa-directed drugs. At present, we are investigating
whether SENP1 and/or SENP2 are indeed TopoIIa deSU-
MOylating enzymes; whether a molecular link between
geminin-induced TopoIIa phosphorylation, SUMOylation
and deSUMOylation exists; and whether using inhibitors
of deSUMOylating enzymes in combination with
TopoIIa-directed drugs could be used to treat breast can-
cers with high geminin levels.
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cell death induced by two different types of TopoIIa
drugs. It has been proposed that cells with low levels of
TopoIIa respond better to the types of drugs that inter-
fere with the catalytic activity of the enzyme (for exam-
ple, ICRF187 and ICRF193), while cells with high
TopoIIa levels are most resistant [73,74]. This could
explain why, compared to uninduced Gem9 cells,
induced Gem9 cells were resistant to these drugs, since
geminin overexpression reduced the level of TopoIIa on
the chromatin. The other types of TopoIIa drugs (for
example, etoposide and doxorubicin) have the potential
to induce DNA DSBs by stabilizing TopoIIa on DNA
and prevent its religation activity during chromosome
decatenation [73,74]. It has also been proposed that
these drugs induce a DSB for every drug-stabilized
TopoIIa enzyme. Thus sensitivity to this type of drugs
increases with the level of the chromosome-bound
TopoIIa. Low chromosome-bound TopoIIa was
detected in cells expressing endogenously (for example,
MDAMB231) or exogenously (induced Gem9), so over-
expression of geminin could explain resistance to this
type of drug as well. This important aspect of our study
implies that the efficacy of all types of TopoIIa-directed
drugs should increase if combined with geminin
inhibitors.
Our previously published results [12] and those pre-
sented in this study are in principle agreement with
those published recently by Zhu et al.[ 7 5 ] .T h o s e
authors claimed that selective killing of cancer cells
could be achieved by inhibiting geminin activity.
Whereas they claimed that normal cells depleted of
geminin continue to proliferate normally [75], we
showed earlier that geminin silencing inhibited progres-
sion of immortalized HME cells from the M to G1
phase with minimal effect on S-phase progression.
Furthermore, they proposed that cancer cells depleted of
geminin specifically rereplicate their genomes and that
their nuclei became giant and underwent apoptosis [75].
However, we proposed that geminin has a fundamental
cytokinetic function, whereas its S phase is redundant.
This discrepancy could be due to differences in the cell
types and/or the techniques used. Another possible rea-
son for this incongruity is that the system cells used in
the Zhu et al. study continued to express cyclin A [75],
while in the HME cells we observed no cyclin A expres-
sion in geminin-silenced cells [12]. It would be interest-
ing in future studies to determine whether, in breast
cancer cell lines, for example, geminin silencing also
induces rereplication as reported by Zhu et al. [75].
However, we doubt this will be the finding, because in a
future publication (unpublished data, W. M. ElShamy)
we will show that continuous geminin silencing (with
three different small hairpin RNA) inhibits the
proliferation of MDAMB231 cells in vitro as well as
tumor formation in a mouse xenograft model. Also in
contrast to the data presented by Zhu et al. [75], in our
work it is geminin overexpression, not its silencing in
HME cells, that triggers the formation of cells contain-
ing > 4 N DNA content in vitro. Furthermore, our work
shows tetraploid and/or aneuploid karyotyping and giant
nuclei both in vitro and in a mouse xenograft model in
geminin overexpressing cells. Given these apparent dif-
ferences, only our overall conclusions are in accord with
those of Zhu et al. [75]. We also propose that inhibiting
geminin expression and/or activity should selectively kill
cancer cells overexpressing geminin (unpublished data,
W. M. ElShamy).
Decreased repair of chromosomal DSBs can lead to
genome instability, including mutation, translocation
and aneuploidy, all of which are hallmarks of many can-
cers [76-79]. Interestingly, specific Chk1 and H2AX
phosphatase upregulation in geminin overexpression led
to their inactivation in Gem9 cells (see Results section).
Taken together, our present findings suggest that
geminin overexpression induces the formation of aneu-
ploid, aggressive and drug-resistant breast cancer cells
(see model in Additional file 7). Geminin silencing pre-
vents decatenation because it blocks TopoIIa’s access to
chromosomes and its function therein (see model in
Additional file 7). Thus, in combination, our data pro-
vide an intriguing molecular explanation for the high
percentage of patients in whom TopoIIa-directed treat-
ment fails. We propose that etoposide, doxorubicin or
any other drugs that target TopoIIa function will be
more beneficial when combined with anti-geminin che-
motherapeutic agents.
Conclusions
In summary, our data provide strong evidence that
geminin plays a critical role in mitotic chromosome
decatenation and/or segregation. The role of geminin
in these processes reflects its ability to influence
TopoIIa chromosome localization and activity during
the G2/M/early G1 phase. The specific timing of gemi-
nin’s association with chromosomes and its regulation
of TopoIIa chromosome localization and function in
the G2/M/early G1 p h a s ef i tt h er o l eo fg e m i n i ni nt h e
induction of proper cytokinesis that we proposed ear-
lier [12]. Our results have established a significant role
for geminin via its functional and physical interactions
with Cdc7 and/or CKIε and TopoIIa, respectively, in
the complex process of mitotic chromosome segrega-
tion and execution of proper cytokinesis. As such,
geminin represents an extremely attractive target for
chemotherapy interventions for aggressive breast can-
cer, either alone or in combination with TopoIIa
drugs.
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insight into how geminin could be involved in gene
amplification and translocation in cancer. We suggest
that lack of religation during the decatenation cycle by
prematurely releasing TopoIIa from the decatenation
sites can lead to illegitimate repair and genome rearran-
gement. Our data also lead us to question previous
assumptions concerning the existence of a checkpoint
for preventing cells with an incompletely replicated and/
or segregated genome from entering mitosis and becom-
ing aneuploid.
Additional material
Additional file 1: Geminin silencing induces chromosome bridges.
Unlike control silenced (siLuc) human mammary epithelial (HME) cells
(A), geminin silencing (siGem) (B) and topoisomerase IIa silencing
(siTopoIIa) (C) induced chromosome bridge formation. Cell division cycle
7 silencing (siCdc7) (D) and casein kinase Iε silencing (siCKIε)
overexpression (G) did not affect chromosome segregation in HME cells.
However, siCdc7 or CKIε overexpression restored chromosome
segregation in siGem cells (E) and (H), respectively, and not siTopoIIa
cells (F) and (I), respectively.
Additional file 2: Synchronization of HME cells. HME cells were
synchronized using growth factor starvation (72 hours) and then were
taken as G0/G1 phase (A) following the 72 hr. After addition of growth
factors, cells reached S phase 16 hours later (B),G 2/M phase 22 hours
later (C) and M/G1 phase 28 hours later (D).
Additional file 3: Expression of several proteins in siGem cells. (A)
Trapped in agarose DNA immunostaining assay-processed HME cells
stained with Hoechst 33258 blue, TopoIIa and geminin. (B) Expression of
selected proteins in HME cells 72 hours following transfection with
control siLuc or geminin small interfering RNA. pChk1, phosphorylated
checkpoint protein 1. (C) Expression of Cdc7, geminin or TopoIIa in HME
cells depleted by control siLuc, siGem, siCdc7 or siTopoIIa. (D) Analysis
of DNA immunoprecipitated by anti-TopoIIa antibody from MDAMB231
cells after luciferase (control) or geminin silencing for 72 hours and the
treatments indicated during the last 24 hours. DMSO, dimethyl sulfoxide;
IP, immunoprecipitation; PHA, PHA767491. (E) Analysis of glutathione S-
transferase (GST) alone or GST-geminin purification using Coomassie blue
stain.
Additional file 4: Geminin silencing abrogates TopoIIa activity.
Decatenation of k-DNA using TopoIIa immunoprecipitated from control
or geminin-silenced cells for 72 hours. In both cases, the cells were
treated with solvent, 10 μM TopoIIa inhibitor etoposide, 10 μM CKIε
inhibitor IC261 or 10 μM Cdc7 inhibitor PHA767491.
Additional file 5: Expression of several proteins in geminin-silenced
or geminin-overexpressing cells. (A) Expression of the indicated
proteins in MDAMB231 cells following geminin silencing detected using
immunoblotting. (B) Expression of the indicated mRNA in control or
PHA767491-treated cells detected using RT-PCR. EGF, epidermal growth
factor; EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; bFGF, basic fibroblast growth factor; ErB2,
human epidermal growth factor receptor 2. (C) Expression of the
indicated proteins in uninduced or induced (72 hours) Gem9 cells after
detection using immunoblotting. Dox, doxycycline. (D)
Coimmunoprecipitates of the indicated proteins with anti-geminin
antibody from the chromatin of S-phase HME or induced Gem9 cells (72
hours) (left) or expression of the indicated proteins in whole cell extracts
of S-phase HME or induced Gem9 cells (72 hours). IP,
immunoprecipitation; IB, immunoblotting; SENP1 and SENP2, sentrin-
specific protease enzymes 1 and 2.
Additional file 6: Effects of geminin silencing or overexpression on
DNA damage and drug response. (A) Comet assay comparing induced
Gem9 cells to uninduced Gem9 cells following luciferase, geminin, Cdc7
or TopoIIa silencing. (B) The effect of the TopoIIa drugs doxorubicin,
etoposide, ICRF187 and ICRF193 on the viability of induced Gem9 or
uninduced Gem9 when luciferase, geminin, TopoIIa and Cdc7 were
silenced. (C) Numbers of anaphase or telophase bridges in geminin-
silenced, induced Gem9, induced Gem9 overexpressing Cdc7 or CKIε. (D)
Percentage of cells stained for Hoechst 33258 blue and Cdc7, geminin or
TopoIIa in luciferase- or geminin-silenced cells, uninduced or induced
Gem9 cells, or induced Gem9 when Cdc7 or CKIε was overexpressed.
Additional file 7: Geminin effects on TopoIIa chromosome
localization and function. Schematic model of the proposed effects of
geminin in normal cells (left), geminin-silenced cells (middle) and
geminin-overexpressing cells (right).
Abbreviations
Cdc7: cell division cycle 7; Cdk1: cell division kinase 1; Chk1: checkpoint
protein 1; CKIε: casein kinase Iε; H2B-GFP: histone 2B fused to green
fluorescence protein; kDa: kilodalton; TARDIS: trapped in agarose DNA
immunostaining; SENP: sentrin-modified protein; TopoIIα: topoisomerase IIα.
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